BSD Medical Reports German Radiation Oncology Society 2012 Deep Hyperthermia Treatment Guidelines Support BSD-2000 Technology

BSD Medical Corporation (NASDAQ: BSDM) today announced that the German Society of Radiation Oncology (DEGRO) has published quality assurance guidelines for deep hyperthermia that support the advanced phased array technology utilized in the BSD-2000 Hyperthermia System. The press release from DEGRO states that the addition of hyperthermia to standard radiotherapy and/or chemotherapy improves the outcome for patients with high risk sarcomas, breast cancer recurrence, superficial tumors, head and neck cancer, cervical cancer, pancreatic cancer, bladder cancer, and rectal cancer. The press release explains that DEGRO is issuing quality assurance guidelines for deep hyperthermia equipment that have been agreed on by a consortium of treatment centers and that the guidelines are expected to improve the delivery of deep hyperthermia. The BSD-2000 Hyperthermia System provides the quality assurance and treatment delivery requirements included in the DEGRO press release for effective delivery of deep hyperthermia.

About DEGRO

The German Society of Radiation Oncology (DEGRO – Deutsche Gesellschaft für Radio-Onkologie) is the largest radiation oncology organization in Germany and has more than 2,500 members. The world’s longest running scientific journal in radiation oncology, “Strahlentherapie und Onkologie,” is the official publication of DEGRO.

About the BSD-2000 Hyperthermia System

The BSD-2000 – developed and patented exclusively by BSD – delivers localized therapeutic heating (hyperthermia) by applying radiofrequency (RF) energy. The BSD-2000 creates a central focusing of energy that can be electronically focused to target the shape, size and location of the tumor, thus providing dynamic control of the heating delivered to the tumor region. The BSD-2000 has Humanitarian Device Exemption (HDE) marketing approval from the U.S. Food and Drug Administration (FDA) for use in conjunction with radiation therapy for the treatment of cervical cancer patients who are ineligible for chemotherapy. The BSD-2000 also has CE (Conformité Européenne) Marking approval for the commercial sale in Europe. CE Marking approval is also recognized in many countries outside of the EU.

If you liked this article you might like

5 Under-$10 Stocks Setting Up to Trade Higher: Must-See Charts

5 Hated Earnings Stocks You Should Love

5 Stocks Under $10 Set to Soar

4 Stocks Under $10 Making Big Moves

5 Stocks That Make Prime Acquisition Targets